MARIA LUIZA NOGUEIRA DIAS GENTA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
19 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 19
conferenceObject RETROSPECTIVE ANALYSIS OF RADICAL HYSTERECTOMY IN A SINGLE BRAZILIAN CANCER CENTER(2016) CARVALHO, J. P. Mancusi de; GENTA, M. L. Nogueira Dias; SADALLA, J. C.; NOBREGA, F. de Souza; ORTOLAN, N. Macerox; CARVALHO, J. PaulaconferenceObject In Bag Morcellation: details and logistics of the technique(2016) FERNANDES, R.; ARAUJO, M.; SILVA, A. Silva e; CARVALHO, P. Mancusi de; ANTON, C.; GENTA, M. L. Nogueira Dias; RIBEIRO JR., A. Dias; SAMPAIO, D.; MIGLINO, G.; SADALLA, J. C.; CARVALHO, J. Paula- BORDERLINE OVARIAN TUMORS-10 YEARS SINGLE CENTER EXPERIENCE(2019) FERNANDES, R.; ANTON, C.; SILVA, A. Silva e; CARVALHO, J. P. Mancusi; ARAUJO, M.; GENTA, M. L. Dias; SAMPAIO, D.; MIGLINO, G.; DIAS JR., A.; SADALLA, J. C.; CARVALHO, J. Paula
- Role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high-grade serous ovarian carcinoma(2021) LOPES, Andre; GENTA, Maria L. N. D.; MIRANDA, Vanessa da Costa; ARANHA, Andrea; LOPEZ, Rossana V. M.; PIATO, Dariane S. A. M.; ANTON, Cristina; CARVALHO, Filomena M.; DIZ, Maria del Pilar Esteves; CARVALHO, Jesus P.Introduction We analyzed the role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy (NACT) cycles for advanced high-grade serous ovarian carcinoma. Materials and Methods We retrospectively reviewed patients with advanced ovarian carcinoma who underwent NACT with carboplatin-paclitaxel between 2008 and 2016. Patients were included only if they had FIGO IIIC-IVB high-grade serous carcinoma with clinically negative lymph nodes after six NACT cycles (carboplatin-paclitaxel) and underwent complete or near complete cytoreduction. Patients with partial lymphadenectomy or bulky nodes were excluded. Patients who underwent systematic pelvic and aortic lymphadenectomy and those who did not undergo lymph node dissection were compared. Progression-free and overall survivals were analyzed using the Kaplan-Meier method. Results Totally, 132 patients with FIGO IIIC-IVB epithelial ovarian carcinoma were surgically treated after NACT. Sixty patients were included (39 and 21 in the lymphadenectomy and nonlymphadenectomy group, respectively); 40% had suspicious lymph nodes before NACT. Patient characteristics, blood transfusion numbers, and complication incidence were similar between the groups. In the lymphadenectomy group, 12 patients (30.8%) had histologically positive lymph nodes and the surgical time was longer (229 vs. 164 min). The median overall survival in the lymphadenectomy and nonlymphadenectomy groups, respectively, was 56.7 (95% CI 43.4-70.1) and 61.2 (21.4-101.0) months (p = 0.934); the corresponding disease-free survival was 8.1 (6.2-10.1) and 8.3 (5.1-11.6) months (p = 0.878). Six patients exclusively presented with lymph node recurrence. Conclusions Systematic lymphadenectomy after six NACT cycles may have no influence on survival.
- Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study(2019) LOPES, Andre; COSTA, Ronaldo Lucio Rangel; PAULA, Raphael di; ANTON, Cristina; CALHEIROS, Ytauan; SARTORELLI, Vivian; KANASHIRO, Yara Mitie; LIMA, Joao Alves de; YAMADA, Alayne; PINTO, Gabriel Lowndes de S.; VIANNA, Maria Regina; GENTA, Maria Luiza Nogueira Dias; RIBEIRO, Ulysses; SANTOS, Marcelo Oliveira dosObjectives To evaluate the clinical outcomes of epithelial ovarian carcinoma patients who underwent cardiophrenic lymph node resection. Methods We retrospectively reviewed the records of all surgically treated patients with advanced epithelial ovarian carcinoma (stages IIIC-IV) who underwent cardiophrenic lymph node resection between 2002 and 2018. Only those in whom cardiophrenic lymph node involvement was the only detectable extra-abdominal disease were included. Patients with suspected cardiophrenic lymph node metastasis on staging images underwent a transdiaphragmatic incision to access the para-cardiac space after complete abdominal cytoreduction achievement. Data on disease-free survival, overall survival, and surgical procedures performed concurrently with cardiophrenic lymph node resection were collected. Results Of the total 456 patients, 29 underwent cardiophrenic lymph node resection; of these, 24 patients met the inclusion criteria. Twenty-two, one, and one patients had high grade serous epithelial ovarian carcinoma, low grade epithelial ovarian carcinoma, and ovarian carcinosarcoma, respectively. Ten patients had recurrent disease (recurrence group). Fourteen patients underwent cytoreduction during primary treatment (primary debulking group); four underwent cytoreduction after neoadjuvant chemotherapy. Cardiophrenic lymph node resection was performed on the right side in 19 patients, left side in three, and bilaterally in two. The average procedural duration was 28 minutes, with minimal blood loss and no severe complications. Twenty-one patients had cardiophrenic lymph node positivity. The median disease-free intervals were 17 and 12 months in the recurrent and primary debulking surgery groups, respectively. The mediastinum was the first recurrence site in 10 patients. Five patients developed brain metastases. Five patients had an overall survival beyond 50 months. Conclusions Although rare, the cardiophrenic lymph nodes may be a site of metastasis of ovarian cancer. Although their presence might indicate future recurrence, some patients may achieve long-term survival. Resection should be considered in cases of suspicious involvement to confirm extra-abdominal disease and achieve complete cytoreduction.
conferenceObject Human papillomavirus 16 is an independent predictor of better survival among patients with early cervical cancer(2016) GENTA, M. L. N. D.; LEVI, J. E.; MARTINS, T. R.; SADALLA, J. C.; LOPEZ, R. V. M.; CARVALHO, J. P. M.; CARVALHO, J. P.- TOXICITY PROFILE IN PATIENTS SUBMITTED TO NEW STRATEGY FOR THE TREATMENT OF VULVAR CANCER EMPLOYING SENTINEL LYMPH NODE SCINTIGRAPHY, SURGERY, CHEMOTHERAPY, AND RADIOTHERAPY(2019) DIAS- JR., A.; NAJAS, G.; GABRIELLI, F.; CARVALHO, H.; MIGLINO, G.; FARIA, M. B. Sartor; ARAUJO, M.; GENTA, M. L. Nogueira Dias; CARVALHO, J. Paula; BARACAT, E. Chada
conferenceObject NEW APPROACH TO DEFINE PATIENTS WITH LOW RISK LYMPH NODE METASTASIS WITH ENDOMETRIAL CANCER(2015) ANTON, C.; FAVERO, G. M.; SILVA, A. S.; MANCUSI, J. P.; ARAUJO, M. P.; SUAREZ, G. M.; GENTA, M. L. D.; PIATO, D. S. A. M.; DIAS JR., A. R.; FERNANDES, R. P.; SADALLA, J. C.; CARVALHO, J. P.- Autologous heterotopic fresh ovarian graft: technique description(2023) BERTOLAZZI, Marilia Albanezi; FERNANDES, Rodrigo Pinto; GENTA, Maria Luiza Nogueira Dias; BARACAT, Edmund Chada; CARVALHO, Jesus Paula
- LAPAROSCOPIC PARAORTIC LYMPHDENECTOMY BY ANATOMICAL HIGHLIGHTED LANDMARKS(2019) FERNANDES, R.; ALEXANDRE, S. E. S.; ANTON, C.; CARVALHO, J. P. Mancusi; ARAUJO, M.; GENTA, M. L. Dias; SAMPAIO, D.; MIGLINO, G.; DIAS JR., A.; SADALLA, J. C.; CARVALHO, J. P.